Nucleic acid metabolism: the key therapeutic target for myeloid tumors

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Nucleic acid analogs like cytarabine, decitabine, and azacitidine have improved myeloid tumor treatment over 50 years.
• Myeloid tumorigenesis is driven by nucleic acid metabolism, with a notable dependence on de novo nucleotide synthesis.
• This pathway presents a promising therapeutic target for myeloid malignancies.

Purpose of the Study:

• To provide a comprehensive review of nucleic acid metabolism, emphasizing de novo nucleotide synthesis.
• To describe clinically used agents targeting nucleic acid metabolism.
• To discuss recent findings on decitabine's non-epigenetic effects and IMPDH inhibitors in myeloid tumors.

Main Methods:

• Literature review of nucleic acid metabolism and related therapies.
• Analysis of existing clinical agents targeting nucleic acid metabolism.
• Discussion of recent research on decitabine and IMPDH inhibitors.

Main Results:

• Nucleic acid metabolism, particularly de novo synthesis, is critical for myeloid tumor growth.
• Established therapies like cytarabine, decitabine, and azacitidine target nucleic acid metabolism.
• Decitabine exhibits non-epigenetic actions, and IMPDH inhibitors show therapeutic potential in myeloid tumors.

Conclusions:

• Targeting nucleic acid metabolism offers a viable strategy for treating myeloid tumors.
• Further research into decitabine's mechanisms and IMPDH inhibitors could lead to improved therapies.
• Understanding nucleotide synthesis is crucial for advancing myeloid cancer treatment.